Latest News
Logo
Position paper
Available in
English
This document compiles BEUC's recommendations for targeted revision of EU medical devices rules after the EU's public consultation on medical devices rules.
Tools
Available in
English
Europe faces serious challenges: growing shortages, high prices, and innovation that does not fully match patients’ real needs. The EU pharmaceutical legislation's revision comes at a decisive moment, alongside negotiations on the Critical Medicines Act. Both will shape future access to safe, available, and affordable medicines. This reform is a unique chance to improve access, strengthen trust in the regulatory system and healthcare systems’ resilience across Member States.
This two-pager sets out BEUC’s 6 key recommendations for trilogue negotiations to secure real benefits for consumers and patients.
This two-pager sets out BEUC’s 6 key recommendations for trilogue negotiations to secure real benefits for consumers and patients.
Position paper
Available in
English
BEUC’s position paper on the Critical Medicines Act considers that the proposal goes in the right direction but should be further aligned with consumers’ needs and expectations.
Position paper
Available in
English
BEUC’s response to the European Commission’s call for evidence on the Medical Countermeasures Strategy
Press release
Available in
English
Today the European Commission published its Critical Medicines Act which is set to tackle shortages by addressing supply chain vulnerabilities, including through diversification and international partnerships. BEUC considers the proposal goes in the right direction tackling shortages but should go further to ensure consumers pay a fair price.
Tools
Available in
English
During a health crisis, having timely access to effective medicines can be a matter of life or death. When a company does not have enough production capacity, or because it charges unaffordable prices for a patented vaccine or treatment, issuing an EU-wide compulsory license for that medicine can allow other companies to manufacture it. The biggest advantage this would procure is to give EU citizens greater access to essential medicines or medical devices. To ensure swift and effective responses during a health crisis, the process for granting a compulsory license cannot be overcomplicated or contain bottlenecks.